A Single-arm, Open, Multicenter, Phase II Study of Famitinib as greater than or equal to Third Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC).

Trial Profile

A Single-arm, Open, Multicenter, Phase II Study of Famitinib as greater than or equal to Third Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC).

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs Famitinib (Primary)
  • Indications Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 16 Apr 2018 Status changed from recruiting to completed.
    • 15 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top